anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an intestinal function improving composition comprising a turmeric leaf extract as an active ingredient. Specifically, the present invention relates to an intestinal function improving food composition comprising a turmeric leaf extract as an active ingredient; a prebiotic composition; a pharmaceutical composition for preventing or treating inflammatory bowel disease; and a method for producing a turmeric leaf extract having intestinal function improving activities. The turmeric leaf extract according to the present invention has an activity of enhancing the flora of beneficial intestinal bacteria. The expression level of tight junction proteins is increased in the tight junctions of intestinal epithelial cells. In addition to strengthening a protective barrier of an intestinal epithelial cell layer, barrier tight junction integrity can be safely maintained. Thus, the turmeric leaf extract of the present invention can be useful to produce functional foods and prebiotics for improving intestinal functions, and can also be useful as materials of an agent for intestinal disease such as inflammatory bowel disease.
Obesity, defined as a body mass index (BMI) \>30 in kg/m2, has reached epidemic levels in the United States (US). Morbid obesity, which is classified as a BMI\>=40, is the fastest growing obesity category. It has increased 52% between 2000 and 2005, to now affect 15 million US adults. Morbid obesity is associated with serious medical co-morbidities, and these obesity-related diseases have a significant impact on the individual patient, as well as on our healthcare system as a whole. Gastric bypass surgery is the only current effective treatment for MO. Approximately 220,000 operations were carried out in 2008, making it one of the most commonly performed procedures in the U.S. The most common form (80%) of bariatric surgery performed in the U.S. is laparoscopic gastric bypass (LGB). While there has been considerable clinical focus on multidisciplinary pre-surgical screening regarding medical, behavioral, and psychosocial suitability of candidates for bariatric surgery, there is a paucity of post-surgical follow-up examining behavioral adaptation and adherence. The purpose of this study is to examine such post-surgical behavioral components that are relevant to weight loss surgery. Specifically, the investigators will assess the feasibility, reliability, usability, and satisfaction of some newly developed wireless home monitoring technology (i.e., medication box, weight scale, and pedometer) in a group of patients who have recently had gastric bypass surgery. A prospective cohort study design will be conducted. Questionnaire data will be collected and data analysis will be descriptive in nature.
On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
Recent studies have found that glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism can enhance the metabolic efficacy of glucagon-like peptide-1 receptor agonist treatment by promoting both weight-dependent and -independent improvements on systemic insulin sensitivity. These findings have prompted new investigations aimed at better understanding the broad metabolic benefit of GIPR activation. Herein, we determined whether GIPR agonism favorably influenced the pharmacologic efficacy of the insulin-sensitizing thiazolidinedione (TZD) rosiglitazone in obese insulin-resistant (IR) mice. Genetic and pharmacological approaches were used to examine the role of GIPR signaling on rosiglitazone-induced weight gain, hyperphagia, and glycemic control. RNA sequencing was conducted to uncover potential mechanisms by which GIPR activation influences energy balance and insulin sensitivity. In line with previous findings, treatment with rosiglitazone induced the mRNA expression of the GIPR in white and brown fat. However, obese GIPR-null mice dosed with rosiglitazone had equivalent weight gain to that of wild-type (WT) animals. Strikingly, chronic treatment of obese IR WT animals with a long-acting GIPR agonist prevented rosiglitazone-induced weight-gain and hyperphagia, and it enhanced the insulin-sensitivity effect of this TZD. The systemic insulin sensitization was accompanied by increased glucose disposal in brown adipose tissue, which was underlined by the recruitment of metabolic and thermogenic genes. These findings suggest that GIPR agonism can counter the negative consequences of rosiglitazone treatment on body weight and adiposity, while improving its insulin-sensitizing efficacy at the same time.
In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
Risk Summary

There are no data on the presence of topical adapalene gel or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. In animal studies, adapalene is present in rat milk with oral administration of the drug. When a drug is present in animal milk, it is likely that the drug will be present in human milk. It is possible that topical administration of large amounts of adapalene could result in sufficient systemic absorption to produce detectable quantities in human milk (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for adapalene gel and any potential adverse effects on the breastfed child from adapalene gel, or from the underlying maternal condition. 

Clinical Considerations 

To minimize potential exposure to the breastfed infant via breastmilk, use adapalene gel on the smallest area of skin and for the shortest duration possible while breastfeeding. Avoid application of adapalene gel to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.
FIELD: chemistry.SUBSTANCE: invention refers to chemical enzymology and medicines for topical application and aims at treating inflammatory processes accompanying oxidative stress in the eye. Composition which reduces oxidative stress in the eye consists of a phosphate buffer solution and an active substance based on particles of the antioxidant enzyme superoxide dismutase. As an active substance, it contains particles obtained by mixing buffer solutions of superoxide dismutase in concentration of 2.5–10.0 mg/ml and polycation in concentration of 2.5–10.0 mg/ml, stirring and holding mixture, adding a polyanion buffer solution in concentration of 2.5–10.0 mg/ml, stirring and holding the obtained mixture, followed by adding to the mixture an aqueous solution of glutaric aldehyde, taken in an amount which provides a molar ratio with the amine groups of polycation of 0.3–1.5, holding mixture, adding aqueous solution of sodium borohydride in concentration 1–2 mg/ml and cleaning mixture using membrane filtration system with transmission limit of 90–130 kilodalton at final pH of composition 6.8–7.6. Polycation is selected from a group comprising protamine, polylysine and polyarginine. Polyanion is a block copolymer of polyglutamic acid and polyethylene glycol or a block copolymer of polyaspartic acid and polyethylene glycol. Components are used in claimed amounts.EFFECT: use of the invention enables to increase the total yield of superoxide dismutase (SOD) on particle activity from 8 to 47–55 %, as well as to increase stability of values of SOD activity in particles and increase stability of particle size during storage thereof.1 cl, 7 ex
Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
Acute nonvariceal upper gastrointestinal bleeding (ANVUGIB) is a common critical disease in gastroenterology. It refers to the bleeding caused by the non varicose diseases above the ligament of flexor, including the bleeding of pancreaticobiliary tract and the bleeding caused by the diseases near the anastomotic stoma after gastrojejunostomy. Due to the development of modern medical technology, the incidence rate of ANVUGIB has been decreasing in recent years. A US study shows that the incidence rate of ANVUGIB dropped from 78/10 to 61/10 10000 \[1\] from 2001 to 2009. However, the mortality within 30 days of ANVUGIB is still as high as 11% \[2\]. Peptic ulcer bleeding is the most common cause of bleeding in ANVUGIB. The annual incidence rate is 19.4-57/10 million, and the rate of rebleeding within 7 days is 13.9%, and the mortality rate is 30 in 30 days. A study in China shows that compared with the 1990s, the detection rate of high-risk ulcer has increased, but the overall mortality has not decreased significantly \[4\]. Endoscopic hemostasis is the first choice for the treatment of peptic ulcer. The latest guidelines of our country recommend that patients with upper gastrointestinal bleeding with stable hemodynamics should try their best to have emergency gastroscopy within 24 hours after bleeding, and emergency endoscopic hemostasis is feasible for bleeding lesions \[5\]. After endoscopic hemostasis, it is very important to give strong acid suppression therapy to maintain gastric pH above 6.0 in the treatment of peptic ulcer bleeding \[6-9\]. This study is to analyze the effect of endoscopic and drug treatment of ANVUGIB.
BACKGROUND/AIM: Gastric cancer, with its high global incidence and mortality rates, poses a significant challenge due to the rapid decline in patient survival upon metastasis. Understanding and combating metastasis are crucial in improving outcomes. The metastasis suppressor gene CD82 has demonstrated efficacy in inhibiting metastasis across various carcinomas but is frequently down-regulated. However, its role and regulatory mechanisms in gastric cancer remain elusive.
MATERIALS AND METHODS: Utilizing public data, we assessed patient survival in relation to CD82 expression. CD82 expression in gastric cancer cell lines was evaluated via western blotting, and its impact on cell mobility was assessed through wound healing and Transwell assays. The demethylation of CD82 was induced using 5-aza-deoxycytidine, while methylation levels were detected via methylation-specific PCR.
RESULTS: Low CD82 expression correlated with poor prognosis in patients, and down-regulation and over-expression of CD82 significantly affected cell mobility. Treatment with 5-aza-deoxycytidine restored CD82 expression in low-expressing cell lines, highlighting its methylation-dependent regulation.
CONCLUSION: CD82 serves as a pivotal regulator of cell mobility in gastric cancer by suppressing metastasis. Its expression is attenuated in gastric cancer cells through promoter hypermethylation.
Treatment of wounds which result from cuts, abrasions, burns, skin ulcers, skin grafts, and the like, and the promotion of healing. One of the technical problems experienced in this area has been the long healing times generally encountered. Some sensitive areas, such as the cornea, are difficult to treat over prolonged periods. This invention provides a solution to this problem by teaching a composition and use of the composition to promote rapid healing of skin, stromal and corneal wounds, by promoting rapid regeneration of the affected tissue. The method involves topical application of a composition which contains a particular polypeptide. The polypeptide is produced using recombinant DNA techniques, specifically through use of a plasmid designated pY EGF-23. The polypeptide exhibits mitogenic activity similar to that of natural epidermal growth factor. The method and composition have been effectively used in treating both skin wounds and corneal wounds.
We performed a cluster, RCT in child care centers located in six urban settings of Colombia with intermittent tap water availability. A total of 1727 children between 1 and 5 years of age distributed in 42 childcare centers participated in the study. The intervention consisted on installation of ABHS gel dispensers and training on their use by participating children in child care centers. Centers assigned to the control group were recommended to continue with current hand hygiene practices. Child care centers matched by location, size and sanitary conditions were randomly assigned to intervention or control. Cases of Acute Diarrheal Disease (ADD) and Acute Respiratory Infections ARI were identified through teacher reported signs and symptoms of disease and validated by a trained physician. We also monitored adverse events potentially related to ABHS. To compare incidence rates between study arms we modeled the number of episodes of ADD and ARI per child using a Cox proportional hazards multiple regression with random effects.
PURPOSE: As the elderly population grows, the prevalence of dementia is also rapidly increasing worldwide. Metformin, an antidiabetic drug, has been shown to have ameliorative effects on impaired cognitive functions in experimental models. However, studies have generally used young animals. Additionally, although it has a major role in Alzheimer's disease (AD) and memory, literature information about the effects of metformin on the cholinergic system is limited. In this study, we investigated the effects of metformin on memory in a model of scopolamine-induced memory impairment in aged rats. We also examined the effects of metformin on the cholinergic system, which is very important in cognitive functions.
METHODS: Metformin was administered orally to male Wistar rats (20-22 months old) at 100 mg/kg/day for three weeks. Morris water maze (MWM) tests were performed to assess spatial memory. Before the probe test of the MWM test, scopolamine was injected intraperitoneally at a dose of 1 mg/kg. After testing, animals were sacrificed, whole brains were removed, and hippocampus samples were separated for biochemical analysis.
RESULTS: Impaired memory associated with scopolamine administration was reversed by metformin. In addition, metformin administration ameliorated scopolamine-induced changes in acetylcholine (ACh) levels, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and choline acetyltransferase (ChAT) activity.
CONCLUSION: Our results show that metformin may have protective effects in a scopolamine-induced memory impairment model in aged animals by improving cholinergic function. Metformin shows promise in preventing dementia with its dual cholinesterase inhibition and ChAT activation effect.
As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
SOAP COMPOSITION ABSTRACT OF THE DISCLOSURE A soap composition for the treatment of skin conditions and irritations, including 40-50 wt% soy oil, 15-25 wt% coconut oil, 1-10 wt% olive oil, 0.5-5 wt% cocoa butter, 15-25 wt% water, and 5-15 wt% sodium hydroxide. A lotion composition, including 85-99 wt% lotion base, 2-10% neem oil, and 0.5-5% black seed oil. A lip balm composition, including 80-99.999 wt% lip balm base, and 0.001-20 wt% of a composition of castor oil, palm kernel oil, aloe extract, carnauba wax, candelilla wax, cocoa butter, vanilla oil, vanilla, and combinations thereof. A method of treating a skin irritation by applying the soap composition to skin, and relieving the irritation. A method of making a soap composition. A method of treating a skin irritation by applying the lotion composition to skin, and relieving the irritation.
Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
The invention provides a saRNA activating CDH13 gene expression and application thereof. Four cell lines are selected from leukemia cell lines, and saRNAs sequences which effectively up-regulate CDH13-mRNA and protein expression are screened out from the four cell lines. In the present invention, after we transfected CDH13saRNAs, the fold up-regulation of CDH13mRNA was 1.53-2.37 fold. The difference in induction effect may be related to the complexity of the promoter element of the target gene, the kind of cell and the transfection reagent. After successful up-regulation of CDH13 expression we found that the relative activity and cell proliferation capacity of K562, KCL22, KU812 and NB4 cells could be inhibited. Experimental results prove that after the gene is over-expressed, the proliferation of cancer cells can be inhibited, so that the progress of diseases is hindered.
A subset of clear cell renal cell carcinomas (ccRCCs) exhibits various growth patterns that infiltrate the normal renal parenchyma; however, our understanding of its association with cancer aggressiveness is incomplete. Here, we show that the morphology of the tumor interface with normal renal parenchyma is robustly associated with cancer recurrence after surgery, even when compared with the TNM staging system or the World Health Organization/International Society of Urological Pathology (WHO/ISUP) nuclear grade in nonmetastatic ccRCC. Hematoxylin and eosin-stained slides of whole tissue sections from surgical specimens were analyzed using a cohort of 331 patients with nonmetastatic ccRCC treated with radical nephrectomy. The patients were classified into 10 subgroups based on our classification algorithms for assessing the tumor interface with normal renal parenchyma. Among the 10 subgroups, 4 subgroups consisting of 40 patients (12%) were identified to have aggressive forms of nonmetastatic ccRCC associated with poor prognosis and unified as renal parenchymal infiltration or micronodular spread (RPI/MNS) phenotypes. Multivariable analyses showed that RPI/MNS phenotypes were robustly associated with shorter disease-free survival, independently of existing pathological factors including the TNM staging system and WHO/ISUP nuclear grade. The hazard ratio was highest for RPI/MNS (4.62), followed by WHO/ISUP grades 3 to 4 (2.11) and ≥pT3a stage (2.05). In addition, we conducted genomic analyses using next-generation sequencing of infiltrative lesions in 18 patients with RPI/MNS and tumor lesions in 33 patients without RPI/MNS. Results showed that alterations in SETD2 and TSC1 might be associated with RPI/MNS phenotypes, whereas alterations in PBRM1 might be associated with non-RPI/MNS phenotypes. These data suggest that RPI/MNS may be associated with aggressive genomic backgrounds of ccRCC, although more comprehensive analyses with a larger sample size are required. Future studies may further elucidate the clinical implications of RPI/MNS, particularly for deciding the indication of adjuvant treatment after nephrectomy.
The safety and efficacy of COTELLIC was established in a multicenter, randomized (1:1), double-blinded, placebo-controlled trial conducted in 495 patients with previously untreated, BRAF V600 mutation-positive, unresectable or metastatic, melanoma. The presence of BRAF V600 mutation was detected using the cobas® 4800 BRAF V600 mutation test. All patients received vemurafenib 960 mg orally twice daily on days 1–28 and were randomized to receive COTELLIC 60 mg or matching placebo orally once daily on days 1–21 of an every 28-day cycle. Randomization was stratified by geographic region (North America vs. Europe vs. Australia/New Zealand/others) and disease stage (unresectable Stage IIIc, M1a, or M1b vs. Stage M1c). Treatment continued until disease progression or unacceptable toxicity. Patients randomized to receive placebo were not offered COTELLIC at the time of disease progression.

The major efficacy outcome was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Additional efficacy outcomes were investigator-assessed confirmed objective response rate, overall survival, PFS as assessed by blinded independent central review, and duration of response.

The median age of the study population was 55 years (range 23 to 88 years), 58% of patients were male, 93% were White and 5% had no race reported, 60% had stage M1c disease, 72% had a baseline ECOG performance status of 0, 45% had an elevated baseline serum lactate dehydrogenase (LDH), 10% had received prior adjuvant therapy, and <1% had previously treated brain metastases. Patients with available tumor samples were retrospectively tested using next generation sequencing to further classify mutations as V600E or V600K; test results were obtained on 81% of randomized patients. Of these, 86% were identified as having a V600E mutation and 14% as having a V600K mutation.

Efficacy results are summarized in Table 7 and Figure 1.

Figure 1 Kaplan-Meier Curves of Overall Survival

The effect on PFS was also supported by analysis of PFS based on the assessment by blinded independent review. A trend favoring the COTELLIC with vemurafenib arm was observed in exploratory subgroup analyses of PFS, OS, and ORR in both BRAF V600 mutation subtypes (V600E or V600K) in the 81% of patients in this trial where BRAF V600 mutation type was determined.